Nanopharm’s pharmaceutical Product Development enables our clients to access our extensive expertise in developing orally inhaled and nasal drug products, from the lab through to the clinic and product registration.

Product development starts with defining the critical material attributes (CMAs) of the device and formulation. This enables pre-selection of lead formulations and processes to best meet the defined target product profile. These formulations and processes are screened to identify critical quality attributes that impact drug product performance. Both formulations and processes are challenged and optimised to ensure that the drug product can be manufactured using the Quality by Design paradigm.

The interaction with Nanopharm was both data and science driven, which was an optimum combination to deliver the most robust formulation by design.

F. Vanhoutte – Scientific Director at Janssen R&D
pro-devlopment-bg2

Respiratory medicines are complex drug products and are typically developed using an iterative approach. This adds significant risk, cost and delays to drug product development and manufacture.

With our knowledge of API and excipients CMAs and our understanding of device/formulation interactions, we are able to accelerate development and manufacture of orally inhaled drug products through a materials-science led approach.

Product development starts with defining the critical material attributes (CMAs) of the device and formulation. This enables pre-selection of lead formulations and processes to best meet the defined target product profile.

step-image

These formulations and processes are screened to identify critical quality attributes that impact drug product performance. Both formulations and processes are challenged and optimised to ensure that the drug product can be manufactured using the Quality by Design paradigm.

Nanopharm’s expert led team work support customers in the development of the following orally inhaled and nasal drug product forms:

  • Solution and suspension nebulizer & soft-mist formulations.
  • Solution and suspension pressurized metered dose inhalers.
  • Carrier-based dry powder inhalers for capsule and blister based devices.
  • High dose drug-only inhaler systems.
  • Solution and suspension nasal products.